Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Commercialization
Pharma
As RevMed preps for ‘historic’ cancer launch, questions linger
An inexperienced RevMed is now responsible for launching the most hotly anticipated cancer drug in years.
Darren Incorvaia
Aug 27, 2026 11:27am
McKesson acquires Maryland CRO for $2.25 billion
Aug 25, 2026 11:22am
Lundbeck partners with Eversana to broaden AI scope
Aug 25, 2026 8:00am
Daiichi promotes Ken Keller to lead new commercialization unit
Aug 24, 2026 4:32am
Valeris taps new strategy chief in patient services vet
Aug 18, 2026 10:51am
BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC
Jul 9, 2026 2:17pm
